LEO Pharma to acquire Bayer’s dermatology unit

LEO Pharma has entered into a definitive agreement to buy Bayer's global prescription dermatology unit. The portfolio to be acquired includes branded topical prescription...

AstraZeneca sells rights for Atacand to Cheplapharm

AstraZeneca has agreed to sell the commercial rights to Atacand (candesartan cilexetil) and Atacand Plus (fixed-dose combination of candesartan cilexetil and hydrochlorothiazide) in Europe...

NanoGenics acquired to advance gene therapy

The Scottish Biotech company Ryboquin, announces the acquisition of Nanogenic Solutions, to form a new product and platform company, Nanogenics Limited. The combined company,...

EUSA Pharma announce acquisition of SYLVANT® from Janssen

EUSA Pharma acquires SYLVANT from Janssen for $115 million

BioIVT acquires Optivia Biotechnology

BioIVT, a provider of research models and services for drug development, has announced that it has acquired Santa Clara, CA-based Optivia Biotechnology and its...

Sanofi and Advent finalise negotiations for the acquisition of Zentiva

Sanofi and Advent International (Advent) have finished negotiations for the acquisition of Zentiva - Sanofi's European generics business. Advent and the companies have signed a Share Purchase Agreement worth €1.9 billion...

Takeda ups bid to $65 billion in negotiations to buy Shire

Takeda has increased offer to buy Shire for a mix of stock and cash worth ~$65 billion

Merck to sell Consumer Health to Procter & Gamble

Merck has sold its global Consumer Health business to Procter & Gamble

Advent in negotiations to acquire Sanofi’s generics business

Advent and Sanofi are in negotiations under which Advent would acquire Zentiva,

Certara acquires Analytica Laser

Certara announced it has acquired Analytica Laser which uses health economics and outcomes research (HEOR)

Latest articles

ViiV Healthcare's long-acting injectable HIV treatment authorised in EU

The first self-administered B-cell therapy for patients with relapsing forms of MS

Novartis receives European and UK licence for Kesimpta®▼(ofatumumab) Ofatumumab is a self-administered targeted B-cell depleting treatment option for adult patients living with relapsing forms of...
MHRA new advice on possible link between COVID-19 Vaccine AstraZeneca and blood clots

MHRA new advice on possible link between COVID-19 Vaccine AstraZeneca and blood clots

The benefits of vaccination continue to outweigh any risks but the MHRA advises careful consideration be given to people who are at higher risk...
Image of a participant being injected with breast cancer treatment

Thousands of patients set to benefit from five-minute breast cancer treatment

An injection that cuts the amount of time breast cancer patients spend in hospital from two and a half hours to as little as...

Popular articles

Image of a person descending a ladder over coronavirus to show New Normal, New Thinking: Life Post COVID-19

New Normal, New Thinking: Life Post COVID-19

New thinking will be required to adapt to the new normal life post COVID-19. I hate to start this article on a negative note, but...
MHRA new advice on possible link between COVID-19 Vaccine AstraZeneca and blood clots

MHRA new advice on possible link between COVID-19 Vaccine AstraZeneca and blood clots

The benefits of vaccination continue to outweigh any risks but the MHRA advises careful consideration be given to people who are at higher risk...
ViiV Healthcare's long-acting injectable HIV treatment authorised in EU

The first self-administered B-cell therapy for patients with relapsing forms of MS

Novartis receives European and UK licence for Kesimpta®▼(ofatumumab) Ofatumumab is a self-administered targeted B-cell depleting treatment option for adult patients living with relapsing forms of...
five-minute breast cancer treatment injection

Twice weekly rapid COVID-19 testing to be available to everyone in England

Access to twice weekly, free, regular, rapid coronavirus (COVID-19) testing from 9 April for everyone in England, the Government has announced. Everyone in England,...
Image of a scientist at their lab to show Study shows existing anti-parasitic drug kills coronavirus within 48 hours

Study shows anti-parasitic drug ivermectin kills coronavirus within 48 hours

A collaborative study led by the Monash Biomedicine Discovery Institute (BDI) with the Peter Doherty Institute of Infection and Immunity (Doherty Institute), a joint...

Subscribe

Sign up to receive your free UK subscription to Pf Magazine and our digital newsletters, for all the essential headlines, Jobs of the Week, and thought-provoking features.

Claim my free subscription